64436-92-6

Usage

Uses

Used in Pharmaceutical Industry:
5-Methoxy-pyridin-3-ylamine is used as a building block for the synthesis of various drug molecules, leveraging its structural features to contribute to the development of new therapeutic agents.
Used in Neurological Disorders Treatment:
5-Methoxy-pyridin-3-ylamine is studied for its potential role in the treatment of neurological disorders, due to its pharmacological properties that may offer therapeutic benefits in managing such conditions.
Used as a Serotonin 5-HT3 Receptor Antagonist:
In the field of pharmacology, 5-Methoxy-pyridin-3-ylamine is recognized for its potential as a serotonin 5-HT3 receptor antagonist, which could be significant in treating conditions related to serotonin dysregulation.
Used as an Anti-Inflammatory Agent:
5-Methoxy-pyridin-3-ylamine has been investigated for its potential use as an anti-inflammatory agent, suggesting that it may contribute to the management of inflammatory conditions by modulating inflammatory responses.

InChI:InChI=1/C6H8N2O/c1-9-6-2-5(7)3-8-4-6/h2-4H,7H2,1H3

Upstream product

• 78156-35-1 3-acetamido-5-methoxypyridine 
• 78156-39-5 3-bromo-5-methoxypyridine 1-oxide 
• 95881-83-7 5-chloro-3-methoxypyridine 
• 50720-12-2 3-bromo-5-methoxypyridine 
• 625-92-3 3,5-dibromopyridine 
• 1336-21-6 ammonium hydroxide 
• 79491-45-5 2,6-dibromo-3-methoxylpyridine 
• 6602-33-1 2,6-dibromopyridin-3-ol 
• 109-00-2 3-HYDROXYPYRIDINE 
• 345231-58-5 C₁₆H₂₀N₂O₄ 
• 78156-34-0 C₁₅H₁₆N₂O₂ 
• 78156-37-3 1-benzyl-3-methoxy-5-oxo-3,4-dehydropiperidine oxime 
• 110038-48-7 3-Chloro-5-methoxypyridine N-Oxide 
• 50866-56-3 1-(benzyl)piperidin-3,5-dione 

Downstream Products

• 77903-28-7 3-Amino-5-methoxy-4-methylpyridine 
• 77903-26-5 3-Methoxy-4-methyl-5-(pivaloylamino)pyridine 
• 77903-30-1 3-Methoxy-4-methyl-5-(phenylseleno)pyridine 
• 77903-31-2 4-Formyl-3-methoxy-5-(pivaloylamino)pyridine 
• 77903-34-5 3-Methoxy-α-phenyl-5-(pivaloylamino)-4-pyridylmethanol 
• 109345-94-0 3-hydroxy-5-methoxypyridine 
• 931126-94-2 methyl 2-{[(5-methoxypyridin-3-yl)amino]sulfonyl}benzoate 
• 931126-95-3 methyl 2-{[(4-methoxypyridin-3-yl)amino]sulfonyl}benzoate 
• 720666-44-4 2,6-dichloro-5-methoxypyridin-3-amine 
• 342603-10-5 tert-butyl 5-methoxypyridin-3-ylcarbamate 
• 1045858-10-3 tert-butyl 5-methoxy-4-methylpyridin-3-ylcarbamate 
• 1185094-00-1 3-amino-5-methoxy-4-methylpyridine hydrochloride 
• 1192255-92-7 (3-methoxy[1,5]naphthyridin-4-yl)methanol 
• 1056877-13-4 3-methoxy-1,5-naphthyridine-4-carbaldehyde 

Relevant academic research and scientific papers

Synthesis and biological evaluation of negative allosteric modulators of the Kv11.1(hERG) channel

We synthesized and evaluated a series of compounds for their allosteric modulation at the Kv11.1 (hERG) channel. Most compounds were negative allosteric modulators of [3H]dofetilide binding to the channel, in particular 7f, 7h-j and 7p. Compounds 7f and 7p were the most potent negative allosteric modulators amongst all ligands, significantly increasing the dissociation rate of dofetilide in the radioligand kinetic binding assay, while remarkably reducing the affinities of dofetilide and astemizole in a competitive displacement assay. Additionally, both 7f and 7p displayed peculiar displacement characteristics with Hill coefficients significantly distinct from unity as shown by e.g., dofetilide, further indicative of their allosteric effects on dofetilide binding. Our findings in this investigation yielded several promising negative allosteric modulators for future functional and clinical research with respect to their antiarrhythmic propensities, either alone or in combination with known Kv11.1 blockers.

Aurora Kinase Modulators and Method of Use

The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

Mild and highly selective palladium-catalyzed monoarylation of ammonia enabled by the use of bulky biarylphosphine ligands and palladacycle precatalysts

A method for the Pd-catalyzed arylation of ammonia with a wide range of aryl and heteroaryl halides, including challenging five-membered heterocyclic substrates, is described. Excellent selectivity for monoarylation of ammonia to primary arylamines was achieved under mild conditions or at rt by the use of bulky biarylphosphine ligands (L6, L7, and L4) as well as their corresponding aminobiphenyl palladacycle precatalysts (3a, 3b, and 3c). As this process requires neither the use of a glovebox nor high pressures of ammonia, it should be widely applicable.

Ligandless copper-catalyzed coupling of heteroaryl bromides with gaseous ammonia

A range of different N- and S-containing heterocyclic bromides can be efficiently coupled with gaseous ammonia in the presence of copper(II) acetylacetonate [Cu(acac)2] as catalyst and in the absence of additional ligands. Unstable aminothiophenes and aminobenzothiophenes can be further reacted in situ to afford functionalized derivatives. Copyright

Process development of a novel azetidinyl ketolide antibiotic

Process development and the multikilogram synthesis of a novel azetidinyl ketolide antibiotic is described. Starting with clarithromycin, the eight-step synthesis features several telescoped operations and direct isolations, which results in a significant improvement in throughput and a major reduction in solvent usage and waste stream volume over the first scale-up campaign. Particular highlights of this effort include the development of an efficient synthesis of 3-hydroxy-1,5-naphthyridine-4-carbaldehyde via a Skraup process and engineering a robust final API synthesis. We also discovered a crystalline monotosylate salt that addressed significant formulation and degradation issues experienced when using the noncrystalline freebase.

Creating an antibacterial with in vivo efficacy: Synthesis and characterization of potent inhibitors of the bacterial cell division protein FTSZ with improved pharmaceutical properties

3-Methoxybenzamide (1) is a weak inhibitor of the essential bacterial cell division protein FtsZ. Alkyl derivatives of 1 are potent antistaphylococcal compounds with suboptimal drug-like properties. Exploration of the structure-activity relationships of analogues of these inhibitors led to the identification of potent antistaphylococcal compounds with improved pharmaceutical properties.

AURORA KINASE MODULATORS AND METHOD OF USE

The present invention relates to chemical compounds having a general formula I {INSERT STRUCTURE HERE} wherein A1-8, D,, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

Therapeutic Compounds

The present invention provides compounds of formula (I), or pharmaceutically acceptable salts or solvates thereof, methods for their preparation, methods for their use, and pharmaceutical formulations comprising them.

NAPHTHYRIDINE DERIVATIVES

The invention concerns naphthyridine derivatives of Formula (Ia) or (Ib) or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, G1, G2, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders or disease states associated with angiogenesis and/or vascular permeability.

Pharmaceutical compositions and methods for use

Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof aryloxyalkylamines, including pyridyloxylalkylamines and phenoxyalkylamines. Exemplary compounds include dimethyl(2-(3-pyridyloxy)ethylamine, dimethyl(4-(3-pyridyloxy)butyl)amine, 2-(3-pyridyloxy)ethylamine, 4-(3-pyridyloxy)butylamine, methyl(3-(5-methoxy-3-pyridyloxy)propyl)amine, ethyl(3-(3-pyridyloxy)propyl)amine, methyl(2-(3-pyridyloxy)ethyl)amine, methyl(3-(6-methyl(3-pyridyloxy))propyl)amine, (3-(3-methoxyphenoxy)propyl)methylamine, (3-(5-chloro(3-pyridyloxy))-1-methylpropyl)methylamine, dimethyl(3-(3-pyridyloxy)propyl)amine, 3-(3-pyridyloxy)propylamine, methyl(4-(3-pyridyloxy)butyl)amine, 3-(5-chloro-3-pyridyloxy)propylamine, methyl(3-(5-isopropoxy-3-pyridyloxy)propyl)amine, (3-(5-chloro(3-pyridyloxy))propyl)methylamine, methyl(3-(5-(phenylmethoxy)(3-pyridyloxy))propyl)amine, methyl(3-(2-methyl(3-pyridyloxy))propyl)amine, (methylethyl)(3-(3-pyridyloxy)propyl)amine, benzyl(3-(3-pyridyloxy)propyl)amine, cyclopropyl(3-(3-pyridyloxy)-propyl)amine, methyl(1-methyl-3-(3-pyridyloxy)propyl)amine, methyl(3-(3-nitrophenoxy)propyl)amine, 1-(3-chloropropoxy)-3-nitrobenzene, (3-(3-aminophenoxy)propyl)methylamine, dimethyl(3-(3-(methylamino)-propoxy)phenyl)amine, methyl(3-tricyclo[7.3.1.0]tridec-2-yloxypropyl)amine, (3-benzo[3,4-d]1,3-dioxolan-5-yloxypropyl)methylamine, 3-(4-piperidinyloxy)pyridine and 3-((3S)-3-pyrrolidinyloxy)pyridine.